US14843C1053 - Common Stock
CASTLE BIOSCIENCES INC
NASDAQ:CSTL (9/16/2024, 8:05:04 PM)
After market: 30.95 0 (0%)30.95
-0.23 (-0.74%)
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 610 full-time employees. The company went IPO on 2019-07-25. The firm is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
CASTLE BIOSCIENCES INC
505 S Friendswood Drive, 2014 San Miguel Dr
Friendswood TEXAS 77546
P: 12817969032
CEO: Derek J. Maetzold
Employees: 610
Website: https://castlebiosciences.com/
On Tuesday, Sotera Health stock hit a key technical milestone, with its Relative Strength Rating climbing to 91, up from 86 the day before.
Here you can normally see the latest stock twits on CSTL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: